Mineralys Therapeutics Other Current Liabilities

Mineralys Therapeutics (MLYS) currently reports a other current liabilities of $18M as of June 2026. That compares with $19M in the prior-year period — down 4.0% year over year. Use the charts on this page to explore Mineralys Therapeutics's other current liabilities history and peer comparisons.

Mineralys Therapeutics's other current liabilities decreased from $19M to $18M — a 4.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Mineralys Therapeutics reported $18M in other current liabilities as of June 2026. That compares with $19M in the prior-year period — down 4.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Mineralys Therapeutics, and consider following MLYS for alerts when major investors trade the stock.